Drug intelligence / Profile preview

Henatinib

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

Henatinib is a small molecule tyrosine kinase inhibitor under development for cancer treatment. It is designed to inhibit specific kinases involved in tumor growth and proliferation, potentially targeting cancers with aberrant kinase activity. Detailed mechanism of action, developer information, and clinical indications are not publicly available or documented in major drug databases as of now.

Other names: Henatinib

Beyond the preview

Go deeper on Henatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Henatinib.

Explore the full profile